Circulating MicroRNAs as Molecular Biomarkers of Atrial Fibrillation Recurrence After Catheter Ablation: A Systematic Review and Candidate-Centered Evidence Map
Biomolecules · 02.11.2026 · 16 (11) · 1590
DOI: 10.3390/biom16111590 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Biomolecules, online erschienen am 02.11.2026. Verfasst von Antônio da Silva Menezes und 4 weiteren Autor:innen. Die Arbeit nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Recurrence after atrial fibrillation (AF) ablation remains difficult to predict. Circulating microRNAs may reflect molecular substrates not captured by established predictors. We mapped recurrence-specific evidence and identified priorities for prospective validation.
Methods
Six databases were searched from inception through 29 August 2026 for adult AF ablation cohorts measuring circulating microRNAs before or around ablation and reporting atrial tachyarrhythmia recurrence. Recurrence-specific reports were assessed with the Quality in Prognosis Studies (QUIPS) tool. A post hoc candidate-centered framework required direct recurrence evidence in at least two analytically distinct samples and support in at least one additional clinical, mechanistic, or analytical domain. Candidate-specific certainty was evaluated with the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework.
Results
Thirty-five publications represented 29 linked programs; 26 recurrence-specific reports represented 25 independent cohorts (3309 enrolled; 3205 analyzed), and nine publications provided longitudinal context. Six microRNAs were identified as priorities for prospective validation: miR-21-5p, miR-150-5p, miR-29b-3p, miR-451a, miR-10b-5p, and miR-320a. Their evidence differed in mature-arm identity, matrix, sampling compartment, assay scale, biological source, and mechanistic support. Candidate-specific certainty was very low.
Conclusions
The evidence supports candidate-specific prospective validation rather than a uniform circulating-microRNA class effect. Standardized preanalytics, mature-arm and carrier attribution, locked assays, and multicenter incremental-prediction studies are required before clinical utility can be established.
Zitieren
APA
Menezes, A. D. S., Silva, A. D. S., Meneses, A. J. D. P. N., Barbosa, A. V. S., & Cruz, A. D. D. (2026). Circulating MicroRNAs as Molecular Biomarkers of Atrial Fibrillation Recurrence After Catheter Ablation: A Systematic Review and Candidate-Centered Evidence Map. Biomolecules, 16(11), 1590. https://doi.org/10.3390/biom16111590
Vancouver
Menezes ADS, Silva ADS, Meneses AJDPN, Barbosa AVS, Cruz ADD. Circulating MicroRNAs as Molecular Biomarkers of Atrial Fibrillation Recurrence After Catheter Ablation: A Systematic Review and Candidate-Centered Evidence Map. Biomolecules. 2026;16(11):1590. doi:10.3390/biom16111590
BibTeX
@article{Menezes2026,
author = {Menezes, Antônio da Silva and Silva, Arthur de Sousa and Meneses, Alcir Júnior de Paula Nunes and Barbosa, Annelyse Vitória Souza and Cruz, Aparecido Divino da},
title = {Circulating MicroRNAs as Molecular Biomarkers of Atrial Fibrillation Recurrence After Catheter Ablation: A Systematic Review and Candidate-Centered Evidence Map},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {11},
pages = {1590},
doi = {10.3390/biom16111590}
}
EUVIMED